Market Cap (In EUR)
199.58 Million
Revenue (In EUR)
506 Thousand
Net Income (In EUR)
-7.66 Million
Avg. Volume
630.00
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.5-21.2
- PE
- -14.18
- EPS
- -0.91
- Beta Value
- 1.126
- ISIN
- GB00BMCLYF79
- CUSIP
- -
- CIK
- -
- Shares
- 15471882.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Heikki Lanckriet Ph.D.
- Employee Count
- -
- Website
- http://www.4basebio.com
- Ipo Date
- 2021-11-23
- Details
- 4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is involved in manufacturing and supplying high quality synthetic DNA products for research, therapeutic, and pharmacological use; and developing target specific non-viral vectors for the efficient delivery of payloads in patients. The company was founded on December 22, 2020 and is headquartered in Cambridge, the United Kingdom.
More Stocks
-
1592
-
BCAUF
-
9384
-
QTRX
-
GUARD
-
044380JOOYONTECH CO., Ltd
044380
-
GAM-PB
-
102710ENF Technology Co., Ltd.
102710